What drove the financial growth for Cryosite (ASX:CTE) in the ten months to April 30, 2026?

Cryosite's strong performance was primarily driven by higher infrastructure utilisation and expanding global clinical trial activity. Increased commercial activity and clinical trials in biologics, cell and gene therapies, and mRNA-based medicines heavily boosted demand for the company's specialised Ultra-Frozen (-80°C) and Cryogenic (-196°C) operating segments.

What were the key revenue and profit metrics for Cryosite (ASX:CTE) in its latest trading update?

Cryosite reported a 22 per cent increase in year-to-date revenue to $13.8 million, up from $11.3 million in the prior corresponding period. Net profit after tax (NPAT) climbed 28 per cent to $1.9 million, while earnings before interest and tax (EBIT) grew 37 per cent to $2.7 million.

How did Cryosite (ASX:CTE) perform at the EBITDA level?

The company's earnings before interest, taxes, depreciation, and amortisation (EBITDA) rose 28 per cent to $3.4 million for the ten-month period. Performance peaked in April 2026, which registered as a record EBITDA month due to substantial operating leverage across all core business streams.

What happened to Cryosite's (ASX:CTE) profit margins during this period?

Cryosite expanded both its EBITDA and NPAT margins by one percentage point. This margin growth brought the company's EBITDA margin to 25 per cent and its NPAT margin to 14 per cent, demonstrating improved operational efficiency across its business segments.

Why did Cryosite (ASX:CTE) incur additional debt, and how did it affect earnings?

Cryosite secured a debt facility with the National Australia Bank (ASX:NAB) to fund the freehold acquisition of its Adderley Street facility. While this move introduced higher interest costs to the ledger, the company still managed to expand its overall profit margins during the ten-month period.

Image for illustrative purposes only. Not a real photo.

Cryosite shares surge on strong earnings growth

Written by Isaac FrancisPublished May. 27 2026Last Updated May. 27 2026

Cryosite (ASX:CTE) has delivered a strong financial performance for the ten months to April 30, driven by rising infrastructure utilisation and expanding global clinical trial activity.

The company secured a 22% increase in year-to-date revenue to $13.8 million, up from $11.3 million in the prior corresponding period.

EBITDA rose 28% to $3.4 million, culminating in a record EBITDA month in April reflecting substantial operating leverage across all core business streams.

The momentum was heavily supported by accelerating demand within Cryosite's specialised Ultra-Frozen (-80°C) and Cryogenic (-196°C) segments, which continue to benefit from heightened clinical trials and commercial activity in biologics, cell and gene therapies, and mRNA-based medicines.

Further down the ledger, the company's EBIT grew 37% to $2.7 million, whilst net profit after tax climbed 28 per cent to $1.9 million.

The board highlighted a one percentage point expansion in both EBITDA and NPAT margins, reaching 25% and 14%, respectively.

The margin growth was achieved despite incurring additional interest costs tied to a National Australia Bank (ASX:NAB) debt facility used to secure the freehold acquisition of its Adderley Street facility.